top of page

Cancer Monitoring Platform. 
Powered by Liquid Biopsy.

The future of oncology is longitudinal.

Altum Sequencing gives clinicians and drug developers the power to see tumor dynamics in real time.

23

Cancer types tested

99%

Specificity in

B-cell lymphoma

97%

of relapses identified

Working Together

FOR PHARMA & Research Partners

We grow with your therapy, not just your trial

From early biomarker strategy to companion diagnostic development and post-approval monitoring, Altum Sequencing supports every phase of your oncology program.

Young Doctor

FOR HEALTHCARE PROFESSIONALS

Real-time tumor monitoring that fits your practice

Whether you're tracking residual disease after standard therapy or navigating the complexity of CAR-T and transplant, both assays run on a single sample, giving you the longitudinal data to make confident decisions at every stage of your patient's treatment.

Altum Sequencing works with pharmaceutical companies, hospitals and clinical research organizations across the world.

"Altum Sequencing’s technology provides highly sensitive molecular insights that complement conventional monitoring, helping us better understand disease evolution and improve long-term patient management."
Dr. Joaquín Martínez

Chairman and Co-Founder

Where can this technology help you?

Altum Sequencing's Role in the Cancer Journey

Our integrated technology platform maps directly onto the key decision points of oncology care, from initial diagnosis through therapy selection, treatment monitoring, and long-term surveillance. Click on each product to learn more.

Platform Mapping by Phase:
Diagnosis

Baseline tumour profiling & biomarker identification

DxPanels
Treatment Effectiveness

MRD monitoring to identify responders vs non-responders

TRACKseq
Emerging Resistance

Early relapse detection & resistance mechanism profiling

EVOseq
Tracking cell-based therapies.

Integrated MRD & pharmacokinetics analysis in allogenic stem cells transplant and CAR-T

DUALseq
Cured or Early Relapse?

Molecular confirmation of remission or early recurrence signal

TRACKseq
Long-term Surveillance

Long-term ctDNA detection up to 5–7 years ahead

TRACKseq

Featured SCIENTIFIC PUBLICATIONS

Latest Publications & News

bottom of page